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ABSTRACT
The  promyelocytic  tumor  suppressor  PML  controls  growth  suppression,  induction  of 
apoptosis, and cellular senescence. It was originally identified as a component of the PML-
RARα oncoprotein  of  acute  promyelocytic  leukemia  (APL).  Moreover,  PML protein  is 
completely or partially lost in a large fraction of human cancers and that loss correlates with 
tumor progression. PML localizes to nuclear matrix-associated macromolecular structures 
known as PML nuclear bodies (PML-NBs), which are dependent on PML for assembly. 
Recently it was discovered that PML is enriched at the endoplasmic reticulum (ER) and at 
the mitochondria-associated membranes, signaling domains involved in ER-to-mitochondria 
calcium ion (Ca2+) transport and in induction of apoptosis. 
PML undergoes  ubiquitin/proteasome-mediated  degradation  in  immortalized  and  tumor 
derived  cell  lines.  PML degradation  depends  on  direct  CK2  phosphorylation  of  PML 
Ser517.
CK2 is a stress-activated serine/threonine protein kinase that is oncogenic and frequently 
overexpressed  in  human  tumor  of  multiple  histological  origins.  In  addition,  CK2 
overexpression due to gene amplification has been reported to be an adverse prognostic 
factor in non-small cell lung cancer.
Interestingly,  PML mutants  that  are  resistant  to  CK2 phosphorylation  display  increased 
tumor suppressive functions in assays measuring apoptosis, replicative senescence, and in 
xenograft models.
PML-NBs contain components of the SUMOylation machinery and both PML and PML-
RARα undergo SUMOylation. However, the biological significance of these events is not 
completely understood. 
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To determine the significance of PML SUMOylation we sought to identify the PML E3 
SUMO ligase. In particular, we identified PIAS1 as a PML E3 SUMO ligase that mediates 
ubiquitin/proteasomal degradation of PML in cancer cells promoting tumorigenesis.
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1. INTRODUCTION
1.1 The promyelocytic leukemia PML
The  promyelocytic  leukemia  gene  (PML),  originally  identified  at  the  breakpoint  of  the 
t(15;17) translocation in acute promyeolocytic leukemia (APL),  is the essential component 
of the PML nuclear body (PML-NB), a nuclear-matrix-associated macromolecular structure 
where multiple tumor suppressor proteins colocalize (Bernardi and Pandolfi, 2007). PML 
deficiency occurs commonly in human cancers and its inactivation in mice leads to cancer 
susceptibility (Trotman et al., 2006; Wang et al., 1998). Moreover, the oncogenic activity of 
the PML-RARα oncoprotein in APL is, at least in part, due to its ability to disrupt PML-
dependent tumor suppressive pathways (Scaglioni  and Pandolfi,  2007; Matsushita et  al., 
2006; Rego et al., 2001). Thus, PML is considered a tumor suppressor. 
PML is a member of the TRIM/RBCC family of proteins,  many members of which are 
ubiquitin ligases that generate subcellular structures through autoassembly (Reymond et al., 
2001; Meroni and Diez-Roux, 2005). Transcription of the PML gene is tightly controlled by 
interferons α,β or γ, but also by p53 (Stadler et al., 1995; de Stanchina et al., 2004), which 
both yield a dramatic increase in the number and the size of the PML-NBs. PML harbors an 
amino-terminal RING finger that directly binds the SUMO E2 ligase UBC9 (Duprez et al., 
1999), two RING-like domains, the B boxes (Tao et al., 2008), and a coiled-coil mediating 
homodimerization (Kastner et al., 1992). For other RBCC/TRIM family members, partner 
binding-specificity often relies on the carboxyl terminus. For PML, a variety of carboxy-
terminal  domains  generated by alternative  splicing yield  isoforms (Jensen et  al.,  2001). 
When expressing single PML isoform in  Pml  -/- cells,  distinct types of PML-NBs were 
observed,  implying that  isoform-specific  sequences contact  different nuclear constituents 
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that  influence  morphogenesis  (Beech et  al.,  2005;  Condemine  et  al.,  2006;  Weidtkamp-
Peters et al., 2008). Yet, because of the coiled-coil, all endogenous isoforms colocalize. The 
most  abundant  (but  perhaps  least  studied)  isoform,  PML-I,  harbors  an  exonuclease-III 
domain, that targets PML to nucleolar caps in stressed or senescent cells (Condemine et al.,  
2007).  In addition to the nuclear localization signal (NLS) present in all PML isoforms, 
PML-I harbors a nuclear export signal (NES) that allows shuttling of all isoforms between 
the two compartments through heterodimer formation (Henderson and Eleftheriou, 2000; 
Beech et al., 2005; Condemine et al., 2006). The most extensively studied isoform, PML-IV, 
induces senescence in primary human fibroblasts (Bischof et al.,  2002) and apoptosis in 
many other cellular settings, at least in part through p53 activation (Guo et al., 2000).
PML undergoes  several  critical  post-translational  modifications,  notably phosphorylation 
and SUMOylation. PML SUMOylation has been implicated in NB-morphogenesis. DNA 
damage-  or  stress-activated  kinases  like  ATM,  ATR,  CHK2,  HIPK2,  CK2,  or  ERK 
phosphorylate  PML,  possibly  regulating  PML  stability,  NB  biogenesis  and  partner 
association (Engelhardt et al., 2003; Hayakawa and Privalsky, 2004; Scaglioni et al., 2008; 
Scaglioni et al.,  2006; Gresko et al.,  2009) and contributing to DNA repair or apoptosis 
control.
PML is ubiquitously expressed, albeit at very low levels,  and PML-NBs are detected in 
almost  any cell  of  the  developing  embryo  or  the  adult  organism.  Nonetheless,  PML is 
markedly  up-regulated  upon  a  number  of  cellular  stresses  including  inflammation, 
oncogenic transformation and proapoptotic stimuli such as for instance ionizing radiation 
(Terris et al., 1995; Ferbeyre et al., 2000; Pearson et al., 2000; Carbone et al., 2002). Under 
these conditions, the number and the size of the PML- NBs (and hence the matrix-associated 
PML fraction),  as  well  as  the  soluble  non matrix  PML nuclear  and cytosolic  fractions, 
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increase (Salomoni,  Bernardi  and Pandolfi,  unpublished observation).  These stimuli  also 
trigger a dynamic reorganization of the PML-NB with transient recruitment and release of 
proteins  from  these  nuclear  organelles,  as  we  will  thoroughly  discuss  throughout  the 
following  paragraphs.  The  PML-NB can  be  therefore  regarded  as  a  multiprotein  stress 
response machinery.
Among the functions attributed to PML and PML-NBs are the regulation of transcription, 
neo-angiogenesis, DNA damage responses, cellular senescence and apoptosis (Zhong et al., 
2000; Bernardi and Pandolfi, 2007; Borden, 2002). 
As soon as a KO model for Pml was created, it became evident that Pml -/- mice and cells 
are protected from multiple and diverse apoptotic stimuli (Fig. 2), such as γ-irradiation and 
CD95/Fas  (Wang  et  al.,  1998).  In  addition,  primary  cells  from  Pml -/-  mice,  such  as 
splenocytes, thymocytes, mouse embryonic fibroblasts (MEFs) and hematopoietic cells, are 
resistant  to  apoptosis  induced  by  CD95/Fas  or  γ-irradiation,  and  many  other  stimuli, 
including ceramide, TNF, IFN, UV light and chemotherapeutic drugs (Wang et al., 1998; 
Louria-Hayon et al., 2003; Wu et al., 2003; Bernardi et al., 2004). In agreement with the 
dominant  negative  role  of  PML-RARα on PML, hematopoietic  progenitors  from PML-
RARα transgenic mice are resistant to similar apoptotic stimuli (Wang et al., 1998). 
The reason why Pml -/- cells are resistant to many apoptotic stimuli is in part because PML 
acts  as a pleiotropic factor that  regulates the function of several  pro- and anti-apoptotic 
factors such as p53, Daxx and c-Jun among others (Bernardi et al., 2008). 
PML is believed to interact with a large number of cellular proteins. However, it is unclear 
how many of these interactions are functional and which of them modulate PML function in 
in vivo settings. This remains one of the key questions in the PML field. 
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The  available  literature  suggests  that  PML is  functioning  as  part  of  a  complex  tumor-
suppressive network. It is well established that PML is an important factor in the regulation 
of  both  p53-  dependent  and  independent  apoptotic  pathways  (Bernardi  et  al.,  2008; 
Takahashi et al., 2004). PML activates p53 by several means: by recruiting p53 to PML-NBs 
by promoting its acetylation and phosphorylation and by binding and inhibiting Mdm2, the 
main negative regulator of p53 (Bernardi and Pandolfi,  2003; Dellaire and Bazett-Jones, 
2004).
In detail,  PML was first  implicated in the control  of p53 activity  as a regulator of p53 
acetylation  in  the  context  of  cellular  senescence,  a  condition  induced by DNA damage 
caused by specific agents or by over-expression of oncogenes (Halazonetis et al., 2008). It  
was shown that, upon expression of a strong oncogene such as RasV12, the full activation of 
p53 depends on the presence of PML, which recruits p53 to the PML-NBs alongside the 
acetyl transferase p300 and in so doing facilitates p53 acetylation (Ferbeyre et al., 2000; 
Pearson et al., 2000).
Later  on,  it  became  clear  that  PML regulates  not  only  p53  acetylation  but  also  p53 
stabilization, by interfering with the ubiquitination of p53 by Mdm2 (Kurki et al., 2003).  
PML can bind to both p53 and Mdm2 (Wei et al., 2003; Zhu et al., 2003) and it has been 
suggested that  PML inhibits  Mdm2-mediated  ubiquitination  of  p53 either  by forming a 
trimeric complex with Mdm2 and p53 (Kurki et al., 2003), or by sequestering Mdm2 away 
from p53 (Bernardi et al., 2004), or yet by promoting p53 de-ubiquitination by the ubiquitin 
protease HAUSP (Everett et al., 1997; Li et al., 2002). In addition, PML blocks p53-Mdm2 
interaction also by promoting p53 phosphorylation by Chk2 and CK1 (Louria-Hayon et al., 
2003;  Alsheich-Bartok et al., 2008). PML may additionally stimulate p53 phosphorylation 
by Chk2 also indirectly, by promoting Chk2 activity. In fact, it was recently shown that, 
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upon DNA damage, PML facilitates Chk2 autophosphorylation and activation (Yang et al., 
2006). Finally, PML promotes the phosphorylation of p53 by HIPK2 (Moller et al., 2003), a 
modification  that  increases  p53-mediated  transcription  of  a  subset  of  promoters  and  is 
associated with UV-induced apoptosis (D'Orazi et al., 2002; Hofmann et al., 2002). 
Despite the large number of publications addressing the issue of the regulation of p53 by 
PML, caution needs to be raised about the fact that the majority of these studies have been 
conducted  in vitro.  Since p53 is a protein regulated by many factors and co-factors,  the 
physiological relevance of these data remains to be established  in vivo. Furthermore, it is 
also important to understand if tumors that have lost PML expression but retain wt p53 can 
be  treated  with  PML-inducing  drugs  to  reestablish  sensitivity  to  pro-apoptotic 
chemotherapy. 
On a final note, most of the functions of PML described so far do depend not only on the  
ability of PML to recruit p53 and/or p53 modifying proteins but also on their translocation 
to the PML-NBs. Consistent with this notion, it was recently reported that cytoplasmic PML 
mutants inhibit p53 activity by acting in a dominant-negative fashion on wt nuclear PML 
(Bellodi et al., 2006). Mutations introducing a stop codon upstream the NLS of PML have 
been identified in patients with aggressive forms of APL, where mutations are found in the 
allele of Pml not involved in the translocation (Gurrieri et al., 2004). In cells expressing wt 
PML, mutant PML accumulates in the cytoplasm, delocalizes nuclear PML into cytoplasmic 
aggregates  and inhibits  p53 transcriptional  activation (Bellodi  et  al.,  2006).   It  must  be 
emphasized that wt cytoplasmic PML isoforms have been characterized and found to be 
critical in regulating TGF-β signaling and anti-viral responses (McNally et al., 2008; Lin et 
al., 2004). 
Although the above mentioned studies did not address the function of wt cytoplasmic PML 
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isoforms in the modulation of cytoplasmic p53 function,  they are nonetheless important 
because  they  indicate  that  patients  bearing  these  or  similar  PML “nuclear  exclusion” 
mutations could prove insensitive to pro-apoptotic drugs acting through p53.
However, PML can also induce apoptosis in a p53-independent manner. After DNA damage, 
for  example,  PML can  induce  apoptosis  by  mediating  Chk2  autophosphorylation  and 
activation (Yang et al., 2006), although the interaction between PML and Chk2 is probably 
more complicated than this simple scenario. On the one hand, Chk2 localizes to PML-NBs 
in undamaged cells and is subsequently released after DNA damage (Yang et al., 2002). On 
the other hand, PML promotes Chk2 autophosphorylation and activation after DNA damage. 
It is unclear, therefore, whether Chk2 autophosphorylation is occurring in the PML-NBs or 
if, perhaps, it is indirectly mediated by PML.
Another protein that can explain the role of PML in apoptosis is Daxx (Bernardi et al.,  
2008). However, the role of Daxx in apoptosis is still not completely understood because 
Daxx has been reported both to enhance and to suppress apoptosis (Salomoni and Khelifi, 
2006). Daxx localization to PML-NBs correlates with its ability to sensitize cells to Fas- and 
splenocyte  activation-induced  apoptosis  (Torii  et  al.,  1999;  Zhong  et  al.,  2000).  It  has 
therefore been proposed that Daxx exerts anti-apoptotic functions outside PML-NBs (Chen 
and Chen, 2003), whereas the pro-apoptotic functions of Daxx, such as the repression of 
anti-apoptotic genes (Croxton et al., 2006) may require its localization to PML-NBs. This 
notion is now challenged by a recent study showing that, in rheumatoid arthritis fibroblasts, 
increased expression of sumo and increased recruitment of Daxx to PML-NBs contributes to 
resistance  to  Fas-induced  apoptosis,  thus  indicating  that  Daxx  pro-apoptotic  or  anti-
apoptotic activity in the PML-NBs may be cell-type specific. In this respect, Daxx could 
regulate gene expression from the PML-NBs differentially in distinct  cell  types. Further 
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work is therefore necessary to elucidate the role of Daxx and its localization to PML-NBs in 
opposing  and  favoring  programmed  cell  death.  By  contrast,  the  role  of  PML is  more 
coherently pro-apoptotic irrespective of the cell type.
Finally,  PML can  also  contribute  to  Fas-induced  apoptosis  by  another  mechanism.  The 
protein FLICE-associated huge protein (FLASH), which functions as a positive regulator of 
Fas-induced apoptosis, localizes to the PML-NBs under steady-state conditions. In response 
to  Fas  activation,  FLASH is  released from PML-NBs and accumulates  in  mitochondria 
where it promotes the activation of caspase-8 (Milovic-Holm et al., 2007).
New findings indicate that PML can act as a suppressor of major oncogenic pathways such 
as  the  PI3K/Akt  pathway.  In  particular,  the  Pandolfi’s  laboratory  has  shown that  PML, 
through  its  ability  to  interact  with  the  protein  phosphatase  PP2A,  inhibits  the  nuclear 
function of Akt, thus leading to suppression of its prosurvival and promitogenic functions 
(Trotman et al., 2006). 
In  Pten +/- animals,  reduction  of  PML gene  dosage  results  in  transition  to  invasive 
carcinoma which is accompanied by increased Akt phosphorylation (Trotman et 
al., 2006); this suggests a genetic interaction between the two pathways. Nonetheless, it is  
not  clear  whether  PP2A  is  delocalized  also  in  PML  tumors.  The  same  group  has 
demonstrated that another component of the PI3K/Akt pathway, the mTOR (mammalian 
target of rapamycin) kinase can associate with PML-NBs (Bernardi et al., 2006). This, in 
turn, results in inhibition of mTOR-dependent HIF1α translation and suppression of tumor 
angiogenesis in vivo. However, it is still unclear to which extent mTOR sequestration acts as 
a  regulatory  mechanism  in  vivo.  A further  contribution  from Pandolfi’s  group  provided 
evidence  that  PML regulates  the  function  of  the  phosphatase  PTEN,  which  is  a  tumor 
suppressor itself and the main inhibitor of the PI3K pathway. This occurs mainly through 
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inhibition of PTEN deubiquitination by HAUSP and its nuclear retention (Trotman et al.,  
2007; Wang et al., 2007). In this respect, nuclear exclusion of PTEN has been associated 
with increased aggressiveness of colon cancer and is predominant in a small number of 
Cowden  disease  cases  due  to  a  mutation  affecting  PTEN  ubiquitination.  It  would  be, 
therefore,  interesting  to  determine  whether  PML loss  in  colon  and  prostate  carcinomas 
correlates with PTEN nuclear exclusion. In summary, it appears that PML is able to affect  
the PI3K pathway at multiple levels. However, it is quite difficult to understand how PML 
could act on the PI3K pathway at so many different levels. One of the potential explanations 
would be that PML action is dependent on the cell or tumor type. This would imply that 
cell/tumor-specific modifications of PML or of its targets, within the PI3K pathway exist to 
allow for selective interactions.  In general, this remains one of the key questions regarding 
the multifaceted function of PML. 
One clear concept that is emerging from the current knowledge about the role of PML in 
apoptosis is that although Pml -/- mice and cells are resistant to a wide variety of apoptotic 
stimuli both in vitro and in vivo, there appears to be no common mechanism to explain the 
general resistance of these cells to apoptosis. Instead, PML-NBs emerge as signaling centers 
that  regulate  the  availability,  post-translational  modification and activation of  many and 
diverse  proteins  implicated  in  apoptotic  pathways.  Most  of  these  proteins  are  upstream 
regulators  of  apoptosis,  in  other  words  they  are  “decision  makers”  that  evaluate  if  the 
conditions are right to trigger apoptosis. Given the general and important role of PML as a 
mediator  of  apoptosis,  our  goal  was  to  investigate  whether  or  not  PML might  also  be 
involved more directly in the execution of apoptosis. 
1.2 The proteasome-ubiquitination/SUMOylation machinery
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The proteasome is composed of a core (20S) particle containing multiple proteolytic sites 
and a 19S regulatory particle that governs access to the core. To enter the core, substrates 
must be amenable to unfolding by a hexamer of ATPases associated with the base of the 
regulatory  particle.  Other  constituents  of  the  regulatory  particle  are  implicated  in  the 
recruitment  of  substrates  (Finley,  2009).  Rpn10  and  Rpn13  interact  with  ubiquitinated 
substrates  through  UIM (ubiquitin-interacting  motif)  domains  and a  Pru  (pleckstrin-like 
receptor  for  ubiquitin)  domain,  respectively.  The  UBL/UBA  family  of  proteins  are 
substoichiometric components of purified proteasomes that bind ubiquitin via their UBA 
(ubiquitin-associated)  domain  and  the  proteasome  regulatory  particle  through  its  UBL 
(ubiquitin-like) domain. They are proposed to remotely scavenge ubiquitinated substrates 
and present them to the proteasome (Figure 1).
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Figure 1. Depiction of the ‘ubiquitin 
receptors’  associated  with  each 
degradative  pathway.  The  domain 
structures  shown  are  for  the  human 
representatives  of  each  protein 
family,  except  for  yeast  Ddi1,  the 
human  ortholog  of  which  does  not 
contain  a  UBA  domain.  CB:  clathrin­
binding  motif;  CC:  coiled  coil; 
ESCRT:  endosomal  sorting  complex 
required  for  transport;  GGA:  golgi­
associated,  gamma  adaptin  ear 
containing, ARF­binding protein; GAE: 
gamma adaptin ear; GAT: GGA and TOM1; 
GLUE:  GRAM­like  ubiquitin­binding  in 
Eap45;  HRS:  HGF  receptor  tyrosine 
kinase  substrate;  LIR:  LC3­
interacting  region;  PB1:  Phox  and 
Bem1;  PRU:  Pleckstrin­like  receptor 
for  ubiquitin;  SH3:  Src  homology 
domain  3;  STAM:  signal  transducing 
adaptor  molecule;  TOM1:  target  of 
myb1;  TSG101:  tumor  susceptibility 
gene  101;  UBA:  ubiquitin­associated 
domain;  UBL:  ubiquitin­like  domain; 
UEV:  ubiquitin  E2  variant  domain; 
UIM:  ubiquitin­interacting  motif; 
VHS:  Vps27,  HRS,  and  STAM;  VPS36: 
vacuolar  protein  sorting  36;  vWFA: 
von  Willebrand  Factor  type  A;  ZZ: 
zinc finger. Note the following gene 
names  and  commonly  used  alternative 
names  also  apply:  p62;  SQSTM1 
(sequestosome),  NDP52;  CALCOCO2, 
UBQLN1;  PLIC1;  DSK2.  Domain 
annotation based on PFAM and UNIPROT.
Particular proteasome-associated ubiquitin receptors have been linked with the degradation 
of specific substrates (reviewed in Finley, 2009).
Substrate  proteins  are  selected  for  modification  of  lysine  residues  by  ubiquitin  through 
interaction with an E3 ligase protein that recruits an E2-enzyme charged with ubiquitin. This 
can result in transfer of a single ubiquitin molecule (monoubiquitination) or coupling of 
further ubiquitin molecules, through integral lysine residues, to form a chain. The seven 
lysines of ubiquitin provide for the formation of different isopeptide chain linkages, which 
adopt different three-dimensional structures, and all of which are represented in eukaryotic 
cells  (Xu et  al.,  2009).  The specific  combination of  E2 and E3 enzymes recruited to  a 
substrate dictates the chain linkage type. The human genome encodes more than 20 different 
types of ubiquitin-binding domains, and proof of principle for linkage specificity of binding 
has  been  established.  One  means  to  achieve  this  is  through  the  spatial  arrangement  of 
tandem  ubiquitin-binding  domains  (UBDs)  either  encoded  in  a  single  protein  or  by 
combining domains within a multimolecular complex, such that simultaneous occupancy of 
two binding sites is restricted to particular chain configurations.
Currently,  there  are  two  families  of  ubiquitin-protein  ligases:  the  HECT  domain 
(homologous to the E6-accessory protein [AP] carboxyl-terminus) enzymes (which form 
thioesters  with  ubiquitin)  and  the  RING  finger  ligases.  The  E6  protein  is  encoded  in 
malignant  forms  of  papilloma  viruses  and  through  recruitment  of  the  cellular  E6-AP 
ubiquitin-protein ligase causes the degradation of p53. The RING finger proteins are either 
in complexes with other proteins essential for ligase activity (the SCF and APC/cyclosome 
complexes) or are associated with putative substrate proteins. The RING finger ubiquitin-
protein ligases bind ubiquitin-conjugating enzymes to facilitate ubiquitinylation of target 
proteins. The latter group of RING finger ligases includes c-Cbl, which is an adaptor for 
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receptor  protein  tyrosine  kinases.  The  c-Cbl  protein  binds  to  phosphorylated  tyrosine 
residues  in  activated  receptors  via  SH2  domains  and  triggers  ubiquitinylation  via  the 
associated ubiquitin-conjugating enzyme (Joazeiro et al., 1999). Other RING finger proteins 
may act as ubiquitin-protein ligases. For example, the protein product of the breast cancer 1 
gene (BRCA1) has a RING finger and is a ubiquitin-protein ligase (Lorick et al., 1999). At 
least 7 other RING finger proteins have demonstrated ubiquitin-protein ligase activity.
Ubiquitin molecules, which are linked together in chains to a protein as a degradation signal, 
are covalently coupled via an isopeptide bond as described earlier utilising the lysine48 
(K48) residue of each ubiquitin. However, chains have also been shown to be linked via four 
of the other six lysines in ubiquitin (K6,K11, K29, and K63). The K63-linked polyubiquitin 
chains appear to play a role in DNA repair. The formation of K63-linked chains is not a 
signal for degradation, which means that attachment of K63-linked chains to proteins is not 
for degradation but for some other purpose, probably in the nucleus in DNA repair. The 
generation  of  K63-linked  chains  is  through  a  heterodimer  composed  of  an  ubiquitin-
conjugating enzyme variant (UEV) and a specific ubiquitin-conjugating enzyme, ubp13p 
(Hofmann and Pickart, 1999). The UEV proteins are homologous to ubiquitin-conjugating 
enzymes  but  lack  the  critical  catalytic  cysteine  residue.  The  UEV proteins  have  been 
implicated in cell transformation and tumour suppression. Again a protein, the ubiquitin-
conjugating enzyme variant, activates an ubiquitin-conjugating enzyme.
The SUMO conjugation pathway has a lot in common with the ubiquitination pathway. Both 
processes involve the use of three enzymes: E1: activating enzyme, E2: conjugating enzyme 
and E3: ligase (Figure 2) (Takahashi et al., 2001). SUMO is bound to its target protein via 
an isopeptide bond formed between an  ε-amino group on the lysine residue on the target 
protein and the C terminal carboxyl group on the SUMO protein (Desterro et al., 1997). The 
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pro-form of SUMO needs to be cleaved prior to protein conjugation. This is carried out by 
isopeptidases, also known as the SENP SUMO deconjugating enzymes (Mukhopadhyay and 
Dasso,  2007).  The  SUMO  activating  enzyme  (E1),  SAE1/2,  commences  the  reaction 
process by interacting with SUMO (activated by SENP enzymes—Figure 2), to form a high 
energy thiolester  bond.  The SUMO conjugating enzyme (E2)  then binds  SUMO via  its 
cysteine  residue  in  its  active  site.  This  intermediate  provides  a  highly  reactive  species, 
important in the final conjugation, usually facilitated by an E3 ligase (Kroetz, 2005). SUMO 
E3 ligases act to either activate Ubc9 or bring Ubc9 and the target protein within close 
proximity of each other, thus enhancing SUMOylation (Ulrich, 2009). They can be regarded 
as  E3  enzymes  as  they  are  able  to  bind  to  the  E2  and  the  substrate  and  facilitate  the 
formation of the bond formed between SUMO and the target protein. It has also been shown 
that a large number of proteins ( 40%) can be SUMOylated without the presence of the∼  
consensus  sequence  (ψKxE),  demonstrating  differences  in  substrate  specificity  (Ulrich, 
2009).
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Figure 2. The SUMO conjugation and deconjugation pathway. The SUMO conjugation 
pathway requires the activity of four enzymes: SENP the SUMO specific protease 
family; E1 composed of 2 subunits Uba2/Aos1; E2—Ubc9 and the E3 ligases. The 
reaction is initiated by cleaving the pro­form of SUMO at its C terminus, to 
its active state, by the SUMO specific proteases (SENPs). Following which, the 
E1 enzyme, a heterodimer of Uba2/Aos1, binds SUMO in an ATP dependant reaction, 
before the transfer to the E2 conjugating enzyme Ubc9. Ubc9 forms a reactive 
bond  between  itself  and  SUMO.  Subsequently,  the  E3  ligase  facilitates  the 
transfer and covalent attachment of SUMO, via an isopeptide bond, to the target 
protein.  This  process  is  in  equilibrium  with  the  SUMO  deconjugation  (SENPs) 
machinery which cleaves the isopeptide bond.
Unlike the ubiquitin (Ub) E1, the SUMO E1 exists as a heterodimer; with each monomer 
corresponding to a particular region of the Ub E1. The SAE subunit Aos1 (SAE1) shares 
similarity with the N terminus of the Ub E1, whilst Uba2 (SAE2), the second component of 
the SAE complex, is similar to the C terminus of the Ub E1 (Johnson et al., 1997). The 
monomers are never found individually and hence it  is assumed that they are unable to 
function independently (Azuma et al., 2001). The SAE complex is responsible for preparing 
SUMO for transfer to the SUMO conjugating enzyme, Ubc9 (Walden et al., 2003). Ubc9 is  
the only known SUMO conjugating enzyme, unlike the ubiquitination pathway where each 
E2 has a specific set of target proteins (Hayashi et al., 2002). Ubc9 contains an active site  
with a cysteine residue which is responsible for binding the SUMO molecule directly to the 
ψKxE sequence found on the target protein (Sternsdorf et al., 1999).
In contrast to SUMO E2s, a larger number of SUMO E3 ligases have been discovered and 
have  been categorized  into  three  types:  the  protein  inhibitor  of  activated  STAT—signal 
transducer and activator of transcription (PIAS) family (Hochstrasser,  2001),  the nuclear 
pore proteins Ran binding protein 2 and nucleoporin 358 (RanBP2/Nup358) (Pichler et al., 
2002) and the polycomb group protein Pc2 (Kagey et al.,  2003).  E3 ligases are usually 
substrate specific with little redundancy found within the system.
The largest group of E3 ligases are the PIAS proteins with four genes in mammals: PIAS1,  
PIAS3,  PIASx  and  PIASγ (Liu  et  al.,  1998).  The  PIAS  E3s  have  a  conserved  region 
consisting of a SAP domain responsible for binding AT rich DNA sequences and an SP-
RING domain  which  binds  to  Ubc9 and promotes  SUMOylation  (Schmidt  and  Müller, 
2002).  They also contain SUMO interaction motifs (SIMs) that are able to directly bind 
SUMO (Rytinki et al., 2009). It has been found that the different PIAS proteins SUMOylate 
distinct sets of substrates, with occasional overlap (Schmidt and Müller, 2002). The second 
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group of E3 SUMO ligases consists of the nuclear pore protein RanBP2 (Nup358) with only 
one known substrate, RanGAP1, a GTPase activating protein important in nuclear transport 
of proteins (Nishimoto, 1999; Saitoh et al., 1997). RanGAP can be SUMO modified in vitro, 
as displayed in  Figure 3. The final family SUMO E3 ligase identified so far is the PC2 
protein part of the polycomb group (Kagey et al., 2003). Pc2 has been shown to SUMOylate 
the transcriptional co-repressor CtBP, localising it to the nucleus (Lin et al., 2003), and to 
co-localise with PcG bodies (Kagey et al., 2003).
SUMO modification is a dynamic process involving both conjugation and deconjugation 
enzymes.  The deconjugation enzymes function by cleaving the isopeptide bond between 
SUMO and the modified protein (Melchior et al., 2003). There are seven isoforms of these 
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Figure 3. In vitro SUMOylation of RanGAP. An in vitro SUMO conjugation 
assay  was  carried  out  to  SUMOylate  the  RanGAP  protein.  RanGAP  was 
incubated with the SUMO conjugation machinery; SUMO1, SAE1/2 and Ubc9 
under the following conditions: 10 µl containing 50 mM Tris pH 7.5, 5 
mM  MgCl
2
 ,  2  mM  ATP,  5  mM  DTT,  100  ng  SAE2/1  (E1),  100–600  ng  UBc9 
(E2), Sumo 2.5 µg and substrate 1–3 µg. The solution was incubated at 
37  C for 2.5 h and the reaction was stopped by the addition of LDS ◦
sample  buffer.  An  additional  control  was  added  where  the  SUMO 
conjugated RanGAP is deconjugated using SENP 1. The conditions for the 
reaction  are  as  follows:  iodoacetamide  was  added  to  the  conjugated 
RanGAP solution at 10 mM and incubated at room temperature for 30 min. 
β­Mercaptoethanol  or  DTT  was  added  at  20  mM  and  left  for  15  min  at 
room temperature. SENP1 was finally added at 10 nM and incubated for 1 
h at 37  C. The reaction was stopped by the addition of LDS buffer. ◦
The samples were run on an SDS­PAGE gel and were then used to detect 
SUMO  conjugation  using  Western  blotting.  The  membranes  were  first 
probed for RanGAP (1:500) and as seen in this figure, an upper band is 
observed, a 10 kDa shift upwards; where free RanGAP is approximately 
32 kDa and SUMOylated Ran GAP is approximately 42 kDa. In the control 
lane with the addition of SENP1, the upper band disappears; suggesting 
RanGAP is SUMO modified in vitro. The same membrane was stripped and 
probed for SUMO 1 (1:1000), as shown in this figure; the upper band is 
also SUMO positive.
isopeptidases, including SENP1, SENP2, SENP3, SENP6 and SENP7 (Mukhopadhyay and 
Dasso, 2007). The SENPs contain a Ulp domain at their C terminus responsible for cleaving 
the isopeptide bond and distinct N terminal domains that regulate their cellular localisation, 
suggesting each SENP has a distinct set of substrates (Mukhopadhyay and Dasso, 2007). In 
addition to their deconjugation role, the SENPs also play an essential role in maintaining the
levels  of  free  SUMO within  the  cell  (Ulrich,  2009).  Other  forms  of  SUMO regulation 
include the E3 ligases and the presence of the consensus motif on target proteins. It has  
previously been stated that 40% of proteins modified by SUMO do not have the typical 
consensus sequence; as such this could also be regarded as another form of regulation. Over 
the last decade a number of groups have investigated how the SUMO pathway is regulated 
in response to different stimuli.  In response to heat shock,  erythroleukemia cells  induce 
transcription of heat shock factor 1 (HSF1). After its translation, HSF1 is phosphorylated 
prior to its SUMOylation, which enhances its DNA binding ability (Hong et al., 2001). It is 
also widely recognised that SUMO alters protein activity by modulating other PTMs, such 
as phosphorylation and ubiquitination. For example, SUMOylation of IκBα, an important 
factor in the inflammatory response, prevents its ubiquitination, and therefore inhibits its 
degradation and subsequent  NF-κB activation and nuclear  translocation (Desterro et  al., 
1998). SUMO can also regulate protein activity by modulating its interactions with other 
macromolecules or proteins. Various models have been proposed such as the addition of 
SUMO by  altering  protein  configuration,  creating  a  new interaction  motif  affecting  its 
function (Johnson, 2004). An interesting example of interaction motifs is arsenic induced 
RNF4 mediated degradation of promyelocytic leukemia (PML) bodies. In the presence of 
arsenic, PML is polysumoylated, and following the recruitment of RNF4, an E3 Ub ligase, 
PML is ubiquitinated and degraded (Tatham et al., 2008).
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1.3 The Casein Kinase 2 CK2
Casein Kinase 2 (CK2) is  a  nuclear-matrix-associated,  highly conserved,  and ubiquitous 
serine/threonine kinase that consists of two catalytic (αα, α'α' or αα') and two β regulatory 
subunits  (Pinna,  2002).  The  regulation  and function  of  CK2 are  not  well  defined,  and, 
traditionally, CK2 has been considered a constitutively nonregulated protein kinase (Allende 
and Allende,  1995). However,  it  has been shown recently that  CK2 is a stress-activated 
protein kinase implicated in prosurvival functions through the phosphorylation of substrates 
such as IκBα. (Ahmed et al., 2002; Kato et al., 2003; Litchfield, 2003). Importantly, CK2 is 
frequently activated in human cancers and can induce mammary tumors and lymphomas 
when  expressed  in  transgenic  mice  (Landesman-Bollag  et  al.,  2001;  Seldin  and  Leder, 
1995).  Traditionally,  CK2  has  been  regarded  as  a  constitutively  active,  ubiquitous 
serine/threonine protein kinase in search of specific physiological functions (Pinna, 2002).
However, several studies have indicated that CK2 plays a critical role in the regulation of 
cell proliferation and survival (Ahmed et al., 2002). The molecular pathways modulating the 
prosurvival properties of CK2 have remained largely unknown, with the exception of its role 
in cellular UV response. In this setting, CK2 is activated by UV radiation in a p38 MAPK-
dependent manner, leading to phosphorylation and degradation of the NF-κB inhibitor IκBα 
(Kato et al., 2003). Furthermore, upon UV irradiation, CK2 complexes and phosphorylates 
p53 at Ser389. MEF cells and mice carrying the p53 S389A mutant in the p53 locus have  
defects  in  the  induction  of  p53  target  genes  and  apoptosis  and  exhibit  increased  skin 
tumorigenesis upon UV irradiation (Bruins et al.,  2004; Keller et al.,  2001). Conversely, 
wild-type  p53  inhibits  CK2  protein  kinase  (Schuster  et  al.,  2001).  These  observations 
support  the notion that  p53 and CK2 functions are interconnected in a tightly regulated 
network.
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2. RESULTS
2.1 PML undergoes ubiquitin/proteasome-mediated degradation
We  determined  whether  PML  undergoes  degradation  through  an  ubiquitin-dependent 
proteasome pathway. Treatment of HEK293 cells with proteasome inhibitor such as MG132 
(data not shown) led to increased PML levels, indicating that PML undergoes degradation. 
Moreover we expressed Flag-tagged PML in HEK293 cells together with HA-ubiquitin and 
treated  them  with  MG132.  Immunoprecipitation  (IP)  followed  by  Western  blot  (WB) 
analysis detected a ladder of HA-marked PML polypeptides, indicating that PML undergoes 
polyubiquitination. We concluded that regulation of PML turnover involves an ubiquitin-
dependent proteasome pathway.
To map the protein sequence necessary and sufficient to direct PML ubiquitinylation, we 
generated a large series of PML deletion mutants that we screened upon transfection with 
HA-ubiquitin in HEK293 cells for the ability to be conjugated to polyubiquitin chains. This 
analysis led to the discovery that a discrete C-terminal PML protein sequence (PML 498–
525) is necessary to allow PML protein polyubiquitination and degradation. Moreover, PML 
498–524 is sufficient to direct polyubiquitinylation of a heterologous protein, such as GFP. 
A summary of these results is provided in Figure 4. We concluded that this sequence is the 
PML degron.
2.2 CK2 phosphorylates the PML degron directly
Protein sequence analysis of the PML degron with the Scansite (http://scansite.mit.edu) and 
ELM  (Eukaryotic  Linear  Motif,  http://elm.eu.org)  prediction  algorithms  revealed  the 
presence of multiple phosphorylation consensus sites for CK2. We found that 6His-tagged 
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full-length  CK2α produced  in  baculovirus  readily  phosphorylates  bacterially  expressed 
PML by an immunocomplex kinase assay. Site directed mutagenesis experiments followed 
by in vitro kinase assays performed in the presence of specific CK2 inhibitors, such as TBB 
and DMAT indicated that PML S517 is the primary CK2 phosphorylation site and suggested 
that phosphorylation of this serine primes phosphorylation of S514. These conclusions were 
confirmed  by  MALDI-re-TOF  mass  spectrometry  experiments  on  recombinant  PML 
proteins  phosphorylated  in  vitro (Scaglioni  et  al.,  2008;  Scaglioni  et  al.,  2006).  These 
experiments led to the conclusion that PML S517 is the major CK2 acceptor site.
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2.3 p38 MAPK activation is required for PML degradation
Since CK2 activation depends on p38 MAPK during cellular stress, we investigated whether 
p38 MAPK activation leads to PML polyubiquitinylation and degradation (Kato et al., 2003; 
Sayed et  al.,  2000).  We found that  several  treatments that  activate p38 MAPK, such as 
osmotic shock, anisomycin, and UV radiation, lead to PML protein polyubiquitination and 
degradation  in  NIH  3T3  cells.  Next,  we  found  that  in  the  context  of  osmotic  shock, 
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Figure 4. a) PML undergoes degradation in HEK293 cells. Endogenous PML and 
actin proteins were detected  by Western blot (WB) in cycloheximide­treated 
cells. b) Proteasome inhibition leads to PML upregulation. HEK293 cells were 
treated with MG132 as indicated. Endogenous PML and actin were detected by 
WB. c) PML is polyubiquitylated. HEK293 cells were transfected and analyzed 
by immunoprecipitation (IP) and WB as indicated (upper panel). Note that the 
membrane  was  not  stripped  in  between  hybridizations.  Ten  percent  of  the 
input lysate was analyzed by WB (lower panel). Ubn = polyubiquitin chains. 
d)  Schematic  representation  of  informative  constructs  used  in  this  study. 
PML modular organization is represented along with its major domains. Boxes 
in light blue and light brown represent PML domains. R: RING finger; B1 and 
B2: B boxes: CC: coiled coil; D: degron; PEST: PEST domain. The column on 
the right indicates whether mutant PML proteins undergo polyubiquitylation. 
e)  Deletion  of  a  critical  PML  C­terminal  protein  sequence  abrogates  PML 
ubiquitylation.  HEK293  cells  were  transfected  as  indicated,  and  their 
lysates  were  analyzed  by  IP  and  WB.  Ten  percent  of  the  input  lysate  was 
analyzed by WB with an anti­HA antibody (lower panel). * = background bands. 
f)  A  critical  PML  C­terminal  protein  sequence  is  sufficient  to  cause 
ubiquitylation  of  EGFP.  HEK293  cells  were  transiently  transfected  with  a 
vector  expressing  EGFP­C,  EGFP­D,  or  wild­type  EGFP.  HA­ubiquitin  was 
cotransfected as indicated and analyzed by IP and WB. Note that the membrane
was not stripped  in between hybridizations. Intensity of the polyubiquitin 
chains is expressed as a ratio between polyubiquitylated EGFP proteins and 
EGFP protein input. g) A critical PML C­terminal sequence is sufficient to 
cause proteasome­mediated degradation of EGFP. HEK293 cells were transiently 
transfected and treated as indicated and were analyzed by WB. Representative 
fields  of  EGFP­positive  cells  obtained  from  the  same  transfection  are 
presented inthe  right panels. Note that MG132 upregulates EGFP­C and EGFP­
D, but not EGFP.
inhibition of p38 MAPK with p38AF, a dominant negative mutant, or the specific inhibitor 
SB202190 efficiently blocks PML degradation in NIH 3T3 cells. Thus, we concluded that 
PML degradation induced by osmotic shock is dependent on p38 MAPK activity.
2.4 CK2 is required for PML degradation
We found  that  TBB  and  TBCA (two  specific  CK2  inhibitors)  abrogate  osmotic  shock 
induced  PML degradation  and  that  two  specific  siRNA oligonucleotides  caused  a  75% 
reduction in CK2α protein in NIH 3T3 cells. In this setting, endogenous PML protein was 
more  than  twice  the  level  observed  in  cells  treated  with  scrambled  siRNA.  These 
experiments confirm that CK2 kinase is required for PML degradation. Furthermore, we 
found  that  abrogation  of  PML S517 resulted  in  complete  resistance  to  sorbitol-induced 
degradation, These experiments further validate that PML phosphorylation by CK2 of PML 
S517 is essential for its degradation (Scaglioni et al., 2008; Scaglioni et al., 2006).
2.5 Mutations at S517 affect PML stability and tumor suppressive function in vitro and in  
vivo
PML is  a  tumor  suppressor  protein  capable  of  inducing  growth  arrest  and  apoptosis 
(Bernardi and Pandolfi, 2007). Therefore, we hypothesized that PML S517A, the mutant 
refractory to CK2-mediated phosphorylation and ubiquitin-mediated degradation, acts as a 
super-tumor suppressor due to its resistance to CK2-mediated degradation. In line with this 
hypothesis, we found that the PML S517A mutant induces replicative senescence in WI38 
human primary fibroblasts and UV induced apoptosis in MEFs unlike wild-type PML. We 
then examined the tumor suppressive role of PML S517A as compared to wild-type PML in 
vivo.  To  this  end,  we  utilized  Colo320DM  cells,  where  PML is  degraded  in  a  CK2 
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dependent  manner,  that  stably  expressing  either  wild-type  or  PML  S517A  proteins. 
Transduced Colo320DM cells were injected subcutaneously into athymic nude mice and 
xenograft growth quantified. These experiments indicated that growth of Colo320DM cells 
expressing PML S517A is reduced by more than 50% when compared to cells expressing 
wild-type PML (Scaglioni et al., 2008; Scaglioni et al., 2006). These data demonstrate that 
PML S517A behaves  as  a  super  active  PML mutant  due  to  defective  CK2  mediated 
degradation.
2.6 CK2-dependent degradation of PML in tumor derived cell lines and in human NSCLC
PML is often partially or completely lost in non-small cell lung cancer (NSCLC) (Scaglioni 
et al., 2008; Scaglioni et al., 2006; Gurrieri et al., 2004; Zhang et al., 2000), while CK2 is 
overexpressed and amplified in NSCLC (O-charoenrat et al., 2004). Therefore, we tested for 
an inverse correlation between the two in a panel of NSCLC cell lines and primary human 
NSCLC specimens. We found that PML protein was barely detectable in A549, H1299, and 
H322 cells.  On the contrary, PML protein was easily detected in H2030,  H157,  H1975, 
H1650, and H358 cells. We performed a CK2 kinase assay on H1299 and H322 and on 
H1650  and  H358  (representative  of  cells  with  high  and  low  PML  protein  levels, 
respectively)  cells.  CK2 kinase  activity  was  strikingly  elevated  in  H322  and  H1299 as 
compared to H1650 and H358 cell lines. We also found an inverse correlation between PML
protein levels and CK2 kinase activity in primary NSCC specimens. We evaluated CK2 
kinase  activity  and  PML  protein  levels  in  18  primary  NSCLC  specimens  and  their 
unaffected counterpart tissue that were snap frozen at the time of their surgical resection. 
PML protein was reduced by at least 50% in 10 out of the 18 tumors analyzed, as compared 
to the unaffected tissue. CK2 kinase activity was increased by at least 50% in nine of these 
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tumors. Therefore, we found a strong association between elevated CK2 kinase activity and 
decreased PML protein level (P = 0.002). These observations strongly suggest that elevated 
CK2 kinase activity leads to PML degradation in primary human NSCLC.
2.7 Pharmacologic inhibition of CK2 leads to a significant anti-tumor effect in vivo
We tested whether CK2 pharmacologic inhibition led to significant anti-tumor effects. For 
these experiments, we used emodin, a specific CK2 inhibitor, to treat nude mice bearing 
Colo320DM xenografts (Yamada et al., 2005). As expected, emodin upregulated PML, but 
not PML S517A in cultured Colo320DM cells. Treatment with emodin in vivo reduced the 
tumor burden by more than 50%. These results suggest that pharmacologic inhibitors may 
have anti-tumor properties (Scaglioni et al., 2008; Scaglioni et al., 2006).
2.8 PML interacts with PIAS1
Yeast two-hybrid screening was carried out according to a standard protocol (Clontech) to 
identify proteins that interact with PML. The bait plasmid pBJKT7-PML4 and the p8op-
LacZ  reporter  gene  plasmid were  first  transformed  in  AH109  yeast  cells  followed  by 
transformation of the library of rat lung cDNA plasmids. Approximately 3.5 × 106 yeast cells 
cotransformed with the bait and cDNAs from a premade rat lung cDNA Matchmaker library 
(Clontech) were screened. About 120 positive clones were selected for their ability to grow 
on plates lacking leucine, tryptophan, histidine, and adenine (Figure 5a) and assayed for β-
galactosidase activity on media supplemented with X-gal (Figure 5b).
The  X-gal  staining  assay  kit is  designed  for  sensitive  and  low-background  in  situ 
visualization  of  cells  carrying  the  lacZ gene.  The  β-galactosidase  enzyme catalyzes  the 
hydrolysis of X-gal (5-bromo-3-indoyl-β-D- galactopyranoside), a β-galactoside.
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Following  fixation  and  incubation  with  the  X-gal  substrate,  cells  transfected  with  a  β-
galactosidase-expressing plasmid will appear blue. These blue cells can be easily visualized 
also by microscopy. Plasmids containing the rat lung cDNAs were isolated from positive 
yeast  cells,  and  their  nucleotide  sequences  were  determined  by  DNA sequencing.  The 
plasmid containing  the  positive  cDNA (Figure  6)  was  isolated  from yeast  by  miniprep 
protocol: the cells of positive clone were resuspended in SE medium (1 M Sorbitol, 50 mM 
EDTA) and 2 mg/ml of the yeast lytic enzime (ICN Biomedical). Following 30 min at 37 °C 
the yeast cells were centrifuged and the pellet was dissolved in HIRT’S solution (10 mM 
Tris-Cl pH 7.5, 50 mM EDTA, 0.2 % SDS) added with 0.5 mg/ml proteinase K (Invitrogen) 
and  incubate  at  50  °C  for  more  than  6  h.  The  cDNA  plasmid  was  extract  by 
phenol/chloroform/isoamyl alcohol (25:24:1) protocol. The aqueous phase was precipitated 
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Figure 5. a) Yeast growth on 
meduim  selection.  b)  X­gal 
staining of colonies.
with the same volume of 20% PEG and 2.5 M NaCl, the nucleic acid was pelleted and 
washed  in  70% ethanol  and resuspended in  10µl  TE (10mM Tris-HCl,  pH 7.5,  1  mM 
EDTA). The plasmid obtained was transformed into E. coli strain DH5α by electroporation. 
In future experiments we will focus on PIAS1 since it was already known by literature being 
an E3 SUMO ligase.
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Figure 6. Yeast colony #2 
shows interaction.
3. DISCUSSION
SUMOylation  is  emerging  as  a  critical  mechanism  regulating  protein  localization  and 
function. This post-translational modification relies on an enzymatic cascade that leads to 
covalent  conjugation  of  SUMO1 and/or  SUMO2/3  to  target  proteins  substrates  (Geiss-
Friedlander and Melchior, 2007). 
PML-NBs contain components of the SUMOylation machinery and both PML and PML-
RARα undergo SUMOylation (Kamitani et al., 1998; Lallemand-Breitenbach et al., 2001). 
However,  the  biological  significance  of  these  events  is  not  completely  understood.  For 
example, it has  been reported that SUMOylation promotes both PML tumor suppressive 
function and PML degradation  (Lallemand-Breitenbach et al.,  2001; Zhong et al.,  2000; 
Ishov  et  al.,  1999;  Shen  et  al.,  2006).  Moreover,  the  striking  anti-leukemic  activity  of 
arsenic trioxide (ATO), a drug commonly used in the treatment of APL, has been attributed 
to  its  ability  to  induce  PML-RARα SUMOylation  followed  by  ubiquitin  mediated 
proteasomal  degradation  (Lallemand-Breitenbach  et  al.,  2001; Tatham  et  al.,  2008; 
Lallemand-Breitenbach et al., 2008). However, it has also been reported that SUMOylation 
of PML-RARα is essential for its leukemogenic activity, a seemingly opposed biological 
outcome  (Zhu et al., 2005). Our work defines a functional network between p38 MAPK, 
p53, CK2, and PML (Figure 7). In addition to its well-established role as a p53 coactivator 
during genotoxic stress (Bernardi et al.,  2004; Guo et al.,  2000; Salomoni and Pandolfi, 
2002),  PML regulates UV response by inducing apoptosis  or cell-cycle arrest in a p53-
independent manner (Salomoni et al., 2005). In this context, the phosphorylation of PML by 
CK2 (and the concomitant phosphorylation of IκBα by CK2) is part of a cellular circuitry 
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that attenuates apoptosis, allowing cells to recover from noxious stimuli.
Under conditions of oncogenic stress, such as the ones triggered by oncogenic Ras, PML is  
activated  and  exerts  its  tumor-suppressive  function  in  concert  with  several  partners, 
including p53. In this context, p53 may inhibit CK2 to achieve maximal PML activity and 
tumor-suppressive effects. On the contrary, when CK2 kinase activity is upregulated (as 
often happens in human cancers), PML is polyubiquitylated and degraded (Figure 7). This 
scenario may be particularly relevant for the pathogenesis of NSCLC, in which increased 
CK2 kinase  activity  may occur because of  either p38 MAPK activation or  CK2α gene 
amplification, a marker of poor prognosis in this disease (O-charoenrat et al., 2004). 
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Figure  7.  Molecular  mechanisms  controlling  PML 
polyubiquitylation.  During  the  cellular  response 
to stress, CK2 kinase controls PML protein levels 
through
integration of upstream p53 and p38 MAPK signals. 
Therapy  with  CK2  or  proteasome  inhibitors  will 
abrogate aberrant PML protein degradation, lead­
ing  to  restoration  of  PML  tumor­suppressive 
properties.
To determine the significance of PML SUMOylation we sought to identify the PML E3 
SUMO ligase. We found that the  E3 SUMO ligases protein inhibitor of activated STAT 
PIAS1and PIASxα,  interact  with  PML in  a  yeast  two-hybrid  screening using  a  cDNA 
library generated from adult human lung tissue as prey.
Subsequently, we will investigate  the PML protein sequence required for interacting with 
PIAS1 by performing co-immunoprecipitation assays with a series of PML deletion mutants 
in HEK293T cells. Moreover, we will characterize whether the presence of PIAS1 affects 
levels of PML-RARα SUMOylation.
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4. EXPERIMENTAL PROCEDURES
4.1 Recombinant Retroviruses, Transductions, and Drug Selection
Recombinant retroviruses were generated by transient transfection of pWzl and/or pBabe 
puro  based  vectors  in  amphotropic  Phoenix  packaging  cell  lines.  48  to  72  hours  after 
transfection, the retroviral supernatants were collected and filtered through a 0.45 μm filter 
and used for transduction. Three to five milliliters of freshly made retroviral supernatants 
containing 4 μg/ml polybrene were added to exponentially growing cells for each 10 cm 
diameter  plate  culture.  After  12  hours  fresh  medium  was  added.  Generally  cells  were 
selected in 150 μg/ml of hygromycin and/or 2 μg/ml of puromycin 48 hours after infection. 
In order to favor a higher number of viral integrations, we selected doubly transduced cells 
in 400 μg/ml of hygromycin 5 μg/ml of puromycin.
4.2 Immunoblotting, Immunoprecipitation, and Chemicals
Cells were harvested in RIPA lysis buffer (150 mM NaCl, 10 mM Tris [pH 7.5], 1% NP40, 
1% deoxycholate,  0.1% SDS,  protease  inhibitor  cocktail  [Roche],  phosphatase  inhibitor 
cocktail [Sigma]). For immunoprecipitation, lysates were precleared with IgG and Protein G 
agarose beads and then incubated with the precipitating antibody for one hour to overnight, 
followed by one hour incubation with protein G agarose beads (Amersham Biosciences). 
Immune complexes were then washed three times in lysis buffer and boiled in gel loading 
buffer. Proteins from total cell lysates or immunoprecipitates were resolved by SDS-poly-
acrylamide  gel  electrophoresis  (SDS-PAGE),  transferred  to  nitrocellulose  membrane, 
blocked in 5% nonfat milk or BSA, and blotted with the appropriate antibody.
The antibodies used in this study were anti-Flag (Sigma); anti-phosphoserine/threonine (BD
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Biosciences); anti-Xpress (Invitrogen); anti-HA (Covance); anti-phospho-p38 MAPK, anti-
p38 MAPK (Cell  Signaling  Technology);  anti-CK2α (Upstate  Biotechnology);  anti-GFP 
(Clontech);  anti-human  PML antibodies  PG-M3  and  H-238  (Santa  Cruz)  and  AB1370 
(Chemicon); anti mouse p16INK4 (sc-1207) and anti p21 (F-5) (Santa Cruz), anti-murine 
PML  S36  (gift  of  Dr.  Scott  Lowe,  Cold  Spring  Harbor  Laboratories);  anti-
phosphoserine/threonine  (BD  Bioscience);  anti-Phospho-PML  S517  was  generated  by 
immunizing rabbits with the peptide: CVISSSED(P)SDAENSSSR, the serum was affinity 
purified. The chemicals were either from Calbiochem or Sigma. SB202190 was used at 10 
μM, MG132 at 10 μM, 4,5,6,7-tetrabromobenzotriazole (TBB) at 50 μM, cycloheximide at 
10 μM, polybrene at  4mg/ml,  sorbitol  at  0.5 M, 3-methyl-1,6,8-trihydroxyanthraquinone 
(emodin) at 50μg/ml in tissue culture cells and at 20 mg/kg daily in vivo. 2-dimethylamino- 
4,5,6,7-tetrabromo-1H-benzimidazole  (K25)  was  a  gift  of  Dr.  Lorenzo  Pinna  (Padua 
University) and was used at 5 μM. Hygromycin and puromycin were from Invitrogen.
4.3 Immunofluorescence and Immunohistochemistry Microscopy
Cell  cultures  were  fixed  in  4%  paraformaldehyde  solution  for  10  minutes  at  room 
temperature,  permeabilized  with  0.1% Triton  X-100 and incubated  with  the  appropriate 
antibodies in 10% goat serum in PBS. For immunohistochemistry, tissue were fixed in 10% 
formalin and embedded in paraffin according to standard procedures.
4.4 In Vitro CK2 Kinase Assays
Bacterially  expressed  Histidine-tagged  wild-type  PML,  S512-514A,  S517A,  S512-517A 
mutants or GST-CS proteins were incubated with Ni-NTA agarose beads for 30 minutes, 
then  they  were  washedtwice  in  kinase  buffer  (4mM  MOPS,  pH  7.2,  5mM  β-glycerol 
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phosphate, 1mM EGTA, 200nM sodium orthovanadate, 200nM dithiothreitol and 50 μM 
ATP [pH 7.5]) and incubated with 0.05 μg purified CK2 (Upstate Cell Signaling Solutions) 
or 20-50 μg of cellular lysate and 2 μCi [γ-32P]-ATP in 40 μl kinase buffer for 30 min at  
30°C. Reactions were stopped by washing twice in kinase buffer and boiling in gel loading 
buffer. Proteins were resolved by 10% SDS-PAGE, stained with coomassie blue and dried 
on Whatman paper. Radiolabeled 32P incorporation was detected by autoradiography.
4.5 In Vitro Phosphorylation-Site Mapping by Mass Spectrometry
Gel-resolved proteins from in-vitro phosphorylation reactions were digested with trypsin, 
batch  purified  on  a  reversed-phase  micro-tip,  and  analyzed  by  matrix-assisted  laser 
desorption/ionization  reflection  time-of-flight  (MALDI-reTOF)  mass  spectrometry  (MS) 
(UltraFlex TOF/TOF; BRUKER; Bremen,  Germany)  for  peptide  mass  fingerprinting,  as 
described (Winkler et al., 2002). This served to confirm the identity of the proteins and to 
locate  differences  between  the  tryptic  peptide  maps  of  the  phosphorylated  and 
unphosphorylated forms. Differential peak m/z values were matched to the fusion protein 
sequence,  allowing  for  the  likely  presence  of  one  or  more  phosphate  groups. 
Massspectrometric  sequencing of  the  putative  phosphopeptides  was  then  carried  out  by 
MALDI-TOF/TOF  MS/MS  analysis  using  the  UltraFlex  instrument  in  “LIFT”  mode. 
Fragment  ion  spectra,  derived from averaging 2,000 laser  shots,  were  inspected for  the 
partial loss of phosphate (98 Da), and for a′′, b′′ and y′′ ions to compare with the computer-
generated  fragment  ion  series  of  the  predicted  tryptic  peptides  to  locate  the  exact  or 
approximate position of phosphoamino acids.
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4.6 Determination of Apoptosis, Replicative Senescence, and Growth Kinetics
Hypodiploid events were evaluated by FACS analysis using propidium iodide staining. For 
growth curves, WI38 cells were plated in triplicate at 2.0 x 104 per well in 12-well plates.  
Population doublings and senescence-associated ß-galactosidase (SA-ß-Gal) was detected as 
described  previously  (Bischof  et  al.,  2002).  Growth  kinetics  of  retrovirally  transduced 
H1299, H322, H2030 and Colo320DM cells were performed by plating in triplicate 3.0 X 
103 cells per well in 12 well-plates. Cells were fixed in formalin and stained with 1% crystal 
violet.
4.7 Yeast two-hybrid system
The  key  to  the  two-hybrid  screen  is  that  in  most  eukaryotic  transcription  factors,  the 
activating and binding domains are modular and can function in close proximity to each 
other without direct binding. This means that even though the transcription factor is split  
into two fragments, it can still activate transcription when the two fragments are indirectly 
connected.
The most common screening approach is  the yeast  two-hybrid assay.  This  system often 
utilizes a genetically engineered strain of yeast in which the biosynthesis of certain nutrients 
(usually amino acids or nucleic acids) is lacking. When grown on media that lacks these 
nutrients,  the yeast  fail  to survive.  This  mutant yeast  strain can be made to incorporate  
foreign DNA in the form of plasmids. In yeast two-hybrid screening, separate bait and prey 
plasmids are simultaneously introduced into the mutant yeast strain.
Plasmids are engineered to produce a protein product in which the DNA-binding domain 
(BD) fragment is fused onto a protein while another plasmid is engineered to produce a 
protein product in which the activation domain (AD) fragment is fused onto another protein. 
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The protein fused to the BD may be referred to as the bait protein, and is typically a known 
protein the investigator is using to identify new binding partners. The protein fused to the 
AD may be referred to as the prey protein and can be either a single known protein or a 
library of known or unknown proteins. In this context, a library may consist of a collection 
of  protein-encoding  sequences  that  represent  all  the  proteins  expressed  in  a  particular 
organism  or  tissue,  or  may  be  generated  by  synthesising  random  DNA  sequences. 
Regardless  of  the  source,  they  are  subsequently  incorporated  into  the  protein-encoding 
sequence of a plasmid, which is then transfected into the cells chosen for the screening 
method. This technique, when using a library, assumes that each cell is transfected with no 
more than a single plasmid and that, therefore, each cell ultimately expresses no more than a 
single member from the protein library.
If the bait and prey proteins interact (i.e., bind), then the AD and BD of the transcription 
factor are indirectly connected, bringing the AD in proximity to the transcription start site 
and transcription of reporter gene(s) can occur. If the two proteins do not interact, there is no 
transcription of the reporter gene. In this way, a successful interaction between the fused 
protein is linked to a change in the cell phenotype.
To link the interaction to a change in observable phenotype, a reporter gene is provided with 
the  upstream activation sequence (UAS) the  binding domain binds  to,  resulting in  gene 
expression in successful cases of interaction. Since its inception in 1989, the technique has 
been combined with a number of different reporter genes that allow selection through a 
simple colour change or through automatic death of cells in which the interaction does or  
does not take place.
The  lacZ reporter  gene  will  allow  the  highlighting  of  cells  where  the  UAS-BD-AD 
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interaction takes place. β-galactosidase, the protein product of the lacZ gene produces a blue 
colouration through the metabolism of X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside), 
which  allows  the  experimenter  to  manually  choose  the  individuals  that  host  proteins 
displaying the required interaction.
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